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Abstract: Excessive type I interferon (IFNα/β) activity is implicated in a spectrum of human 
disease, yet its direct role remains to be conclusively proven. We investigated two siblings with 
severe early-onset autoinflammatory disease and an elevated IFN signature. Whole exome 
sequencing revealed a shared homozygous missense Arg148Trp variant in STAT2, a transcription 
 4 
factor that functions exclusively downstream of innate IFNs. Cells bearing STAT2R148W in 
homozygosity (but not heterozygosity) were hypersensitive to IFNα/β, manifest as prolonged 
JAK-STAT signaling and transcriptional activation.  We show that this gain of IFN activity 
results from the failure of mutant STAT2R148W to interact with ubiquitin specific protease 18 
(USP18), a key STAT2-dependent negative regulator of IFNα/β signaling. These observations 
reveal an essential in vivo function of STAT2 in the regulation of human IFNα/β signaling, 
providing concrete evidence of the serious pathological consequences of unrestrained IFNα/β 
activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.   
One-sentence summary here (125 characters with spaces) 
 
One Sentence Summary:  STAT2R148W impairs an essential regulatory function of STAT2, 
revealing the damage wreaked by excessive IFNα/β activity. 
 
Introduction 
Type I interferons (including IFNα/β) are antiviral cytokines with pleiotropic functions in the 
regulation of cellular proliferation, death and activation. Reflecting their medical importance, 
type I IFNs have been shown to be essential to antiviral immunity in humans (1), whilst their 
potent immunomodulatory effects have been exploited to treat both cancer and multiple sclerosis 
(2, 3).  
IFNα/β also demonstrates considerable potential for toxicity, which became apparent in initial 
studies in rodents (4) and subsequent clinical experience in patients (5, 6). Thus the production 
of and response to type I IFNs must be tightly controlled (7). Transcriptional biomarker studies 
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increasingly implicate dysregulated IFNα/β activity in a diverse spectrum of pathologies ranging 
from autoimmune to neurological, infectious and vascular diseases (8-11).  
The immunopathogenic potential of IFNα/β is exemplified by a group of monogenic inborn 
errors of immunity termed ‘type 1 interferonopathies’, wherein enhanced IFNα/β production is 
hypothesized to be directly causal (12). Neurological disease is typical of these disorders, 
manifest as defects of neurodevelopment in association with intracranial calcification and white 
matter changes on neuroimaging, suggesting that the brain is particularly vulnerable to the 
effects of excessive type I IFN activity (9). A spectrum of clinical severity is recognized, from 
prenatal-onset neuroinflammatory disease that mimics in utero viral infection - Aicardi-
Goutières syndrome (13) - to a clinically silent elevation of IFN activity (14). 
However the central tenet of the type I interferonopathy hypothesis, namely the critical 
pathogenic role of type I IFNs (12), has yet to be formally established (15). Evidence for an IFN-
independent component to disease includes: (i) recognition that other proinflammatory cytokines 
are also induced by nucleic acid sensing which might contribute to pathogenesis (16), (ii) 
imperfect correlations between IFN biomarker status and disease penetrance (14), (iii) the 
absence of neuropathology in mouse models of Aicardi-Goutières syndrome (AGS) despite 
signatures of increased IFN activity (17) and (iv) the observation that crossing to a type I IFN 
receptor deficient background does not rescue the phenotype in certain genotypes (e.g. STING, 
ADAR1) (18, 19), although it does in others (e.g. TREX1 or USP18) (20, 21). Here we provide 
concrete evidence of the pathogenicity of type I IFNs in humans, shedding new light on the 
critical importance of STAT2 in the negative regulation of this pathway.  
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Results 
Severe neurological and systemic inflammatory disease associated with increased IFN signature 
We evaluated two male siblings, born in the UK to second-cousin Pakistani parents. 
Briefly, patient II:3, born at 34+6 weeks with transient neonatal thrombocytopenia, was 
investigated for neurodevelopmental delay at 6 months (which was attributed to compensated 
hypothyroidism). Aged 8 months he presented with the first of three episodes of dramatic 
neuroinflammatory disease, associated with progressive intracranial calcification, white matter 
disease and, by 18 months, intracranial hemorrhage (Fig. 1A). These episodes were associated 
with systemic inflammation and multi-organ dysfunction, including recurrent fever, 
hepatosplenomegaly, cytopenia with marked thrombocytopenia, raised ferritin and elevated liver 
enzymes. Latterly, acute kidney injury with hypertension and nephrotic range proteinuria 
developed (Table 1, supplementary complete case summary, table S1). 
This clinical phenotype was reminiscent of a particularly severe form of type I 
interferonopathy. In keeping with this observation, interferon-stimulated gene (ISG) transcripts 
in whole blood, measured by RNA sequencing (RNA-seq) and RT-PCR, were substantially 
elevated over multiple timepoints at similar magnitudes to recognized type I interferonopathies 
(Fig. 1B-C), notably without evidence of concomitant induction of IFN-independent 
inflammatory pathways (fig. S1). Disease in the proband, which met diagnostic criteria for 
hemophagocytosis but also included features of a thrombotic microangiopathy (Fig. 1D), was 
partially responsive to dexamethasone and stabilized with the addition of the Janus kinase (JAK) 
inhibitor ruxolitinib (Fig. 1E and fig. S2). Sadly however this child succumbed to overwhelming 
gram-negative bacterial sepsis during hematopoietic stem cell transplantation.  
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Patient II:4, his infant brother, presented with abnormal neurodevelopment and 
neuroimaging in the neonatal period, characterized by apneic episodes from 3 weeks of age in 
conjunction with parenchymal calcifications and hemorrhage, abnormal cerebral white matter, 
and brainstem and cerebellar atrophy (Fig. 1A). Blood tests revealed an elevated ISG score (Fig. 
1B-C), anemia, elevation of D-dimers and red cell fragmentation on blood film, together with 
proteinuria and borderline elevations of ferritin and lactate dehydrogenase; renal function was 
normal and blood pressure was on the upper limit of the normal range for gestational age. 
Introduction of ruxolitinib led to prompt suppression of ISG expression in whole blood (Fig. 1E) 
and an initial reduction in apneic episodes, but neurological damage was irretrievable and he 
succumbed to disease at 3 months of age. Notably, mother’s pregnancy with patient II:4 had 
been complicated by influenza B at 23-weeks’ gestation. 
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A rare homozygous missense variant of STAT2 (Arg148Trp) segregates with disease  
Whole exome sequencing analysis of genomic DNA from the kindred, confirmed by Sanger 
sequencing (Fig. 2A-B), identified an extremely rare variant in STAT2 (c.442C>T), which 
substituted tryptophan for arginine at position 148 in the coiled-coil domain of STAT2 
(p.Arg148Trp, Fig. 2C). The Arg148Trp variant was present in the homozygous state in both 
affected children and was heterozygous in each parent and one healthy sibling, consistent with 
segregation of an autosomal recessive trait (table S2). This variant was found in the heterozygous 
state at extremely low frequency in publicly-available databases of genomic variation (frequency 
< 0.00001 in gnomAD (22)) and no homozygotes were reported. A basic amino acid, particularly 
arginine, at position 148 is highly conserved (fig. S3). In silico tools predicted that this missense 
substitution was probably deleterious to protein function (table S2). STAT2 protein expression in 
patient cells was unaffected by the Arg148Trp variant, in contrast to the situation for pathogenic 
loss-of-expression STAT2 variants which resulted in a distinct phenotype of heightened viral 
susceptibility (23, 24) (Fig. 2D). Filtering of exome data identified an additional recessive 
variant in CFH (c.2336A>G, p.Tyr779Cys, fig. S4) present in the homozygous state in II:3, but 
absent from II:4.  We considered the possibility that this contributed to thrombotic 
microangiopathy in the proband, but functional studies of this variant showed negligible impact 
on factor H function (fig. S5).  
 
STAT2R148W enhances cellular sensitivity to type I IFNs 
The transcription factor STAT2 is essential for transcriptional activation downstream of the 
receptors for the innate IFNs-α/β (IFNAR) and - (IFNLR) and their associated JAK adaptor 
proteins. In the current paradigm (25), STAT2 is activated by tyrosine phosphorylation, 
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associating with IRF9 and phosphorylated STAT1 to form the Interferon-Stimulated Gene Factor 
3 (ISGF3) to effect gene transcription by binding to interferon-stimulated response elements 
(ISRE) in the promoters of ISGs. While loss-of-function variants in STAT2 increase 
susceptibility to viral disease (23, 24), evidence here suggested pathological activation. Germline 
gain-of-function variants have been reported in STAT1 (26, 27) and STAT3 (28, 29), but not 
hitherto STAT2. Consistent with the apparent gain of IFN activity associated with mutant 
STAT2R148W, we observed in patient fibroblasts (Fig. 3A-B) and peripheral blood mononuclear 
cells (PBMCs, fig. S6) the enhanced expression of ISG protein products across a range of IFNα 
concentrations. However, basal and induced production of IFNB mRNA by fibroblasts was 
indistinguishable from controls (Fig. 3C); nor was IFNα protein substantially elevated in patient 
samples of cerebrospinal fluid (II:3) or plasma (II:4) as measured by a highly sensitive digital 
ELISA assay (30), albeit samples were acquired during treatment (table S3). Thus, the response 
to type I IFNs, but not their synthesis, was exaggerated. This heightened IFN sensitivity was 
accompanied by enhancement of key effector functions, as revealed by assays of IFNα-mediated 
viral protection (Fig. 3D) and cytotoxicity (Fig. 3E). Collectively, these data indicated that 
STAT2R148W was not constitutively active, but rather resulted in an exaggerated response upon 
IFNα exposure. To confirm that the Arg148Trp variant was responsible for this cellular 
phenotype, we transduced STAT2-null U6A cells (31) and STAT2-deficient primary fibroblasts 
(23) with lentiviruses encoding either wild-type or STAT2R148W, recapitulating the heightened 
sensitivity of cells expressing the latter to IFNα (Fig. 3F-G, fig. S7).  
 
STAT2R148W prolongs IFNAR signaling without impacting STAT2 dephosphorylation 
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To explore the underlying mechanism for heightened type I IFN sensitivity, we first probed 
STAT2 activation in IFNα-stimulated fibroblasts. In control lysates, levels of phosphorylated 
STAT2 (pSTAT2) had almost returned to baseline between 6-24h of treatment despite the 
continued presence of IFNα (Fig. 4A-B). In contrast, pSTAT2 persisted for up to 48h in patient 
cells. This abnormally prolonged pSTAT2 response to IFNα was also observed in PBMCs of 
both patients (fig. S8). Consistent with immunoblot data, immunofluorescence analysis showed 
persistent (≥ 6h) nuclear localization of STAT2 in patient fibroblasts following IFNα treatment, 
at times when STAT2 staining was predominantly cytoplasmic in control cells (Fig. 4C-D, fig. 
S9). This was accompanied by continued expression of ISG transcripts for 36h following the 
washout of IFNα in patient cells as measured by RNA-seq and RT-PCR (Fig. 4E-F). Thus, the 
type I IFN hypersensitivity of patient cells was linked to prolonged IFNAR signaling.  
The IFNAR signaling pathway is subject to multiple layers of negative regulation that target 
STAT phosphorylation directly - through the action of tyrosine phosphatases - or indirectly, by 
disrupting upstream signal transduction (7). Prolonged tyrosine phosphorylation is reported with 
gain-of-function mutations in STAT1, in association with impaired sensitivity to phosphatase 
activity (27). By contrast, we observed no impairment of dephosphorylation of STAT2R148W in 
pulse-chase assays with the kinase inhibitor staurosporine (Fig. 4G-H), implying instead a failure 
of negative feedback upon the proximal signaling events that generate pSTAT2.  
 
Prolonged IFNAR signaling in STAT2R148W homozygous but not heterozygous cells 
To localize this defect, we analyzed by phosflow and immunoblot the successive activation steps 
downstream of IFNAR-ligand binding in EBV-transformed B cells from the proband (II:3) and a 
heterozygous parent (I:2). As was the case for STAT2 phosphorylation, we also observed 
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prolonged phosphorylation of both JAK1 and STAT1 following IFNα treatment (Fig. 5A-D). 
This points to a defect in regulation of the most proximal IFNAR signaling events, upstream of 
STAT2 (7). We observed no evidence of this phenotype in cells bearing STAT2R148W in the 
heterozygous state, consistent with autosomal recessive inheritance and the lack of clinical 
disease or upregulation of IFN activity in heterozygous carriers. This genetic architecture 
provides a notable contrast to gain-of-function mutations affecting other STAT proteins, all of 
which are manifest in the heterozygous state (26-29).  
 
STAT2R148W specifically compromises negative regulation of IFNAR signaling  
Known negative regulators of IFNAR signaling are suppressor of cytokine signaling (SOCS) 1 
and SOCS3 (32), and the ubiquitin specific protease 18 (USP18) (33). SOCS1 and SOCS3 
participate in regulation of additional JAK-STAT signaling pathways, such as those activated by 
IFN and IL6 (34, 35), whereas USP18 acts specifically upon IFNAR signaling (33). To better 
localize the molecular defect in patient cells we examined the signaling responses to 
IFNSTAT1 phosphorylation) and IL6 (STAT3 phosphorylation), based on the prediction that 
defects of SOCS1 or SOCS3 regulation would manifest under these conditions. These 
experiments revealed that regulation of STAT1 and STAT3 phosphorylation was normal in 
patient fibroblasts (fig. S10). Taken together with the absence of evidence of upregulation of the 
IFN and IL6 pathways in the analysis of whole blood RNA-seq data (fig. S1), these 
observations effectively ruled out the involvement of SOCS1 and SOCS3 in the clinical 
phenotype, leading us to suspect a defect of USP18 regulation.  
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To investigate this possibility, patient and control cells were primed with IFNα for 12h, washed 
extensively, rested and restimulated with IFNα or IFNafter 48hIn these experiments, IFNα-
induced pSTAT2 and pSTAT1 were strongly inhibited by priming in control cells, consistent 
with desensitization, a well-established phenomenon of type I IFN biology (36) (Fig. 6A-B). In 
marked contrast, the response to IFNα restimulation in patient cells was minimally suppressed, 
indicating a failure of desensitization. Desensitization has been shown to be exclusively 
mediated by USP18, an IFN-induced isopeptidase (37), through its displacement of JAK1 from 
the receptor subunit IFNAR2 (38, 39) - a function that is independent of its isopeptidase activity 
towards the ubiquitin-like protein ISG15 (33). Importantly, STAT2 plays a critical role as an 
adaptor protein by supporting binding of USP18 to IFNAR2 (40) (Fig. 6C). Both the clinical and 
cellular effects of STAT2R148W resemble homozygous USP18 deficiency, which was recently 
described as the molecular cause of a severe pseudo-TORCH syndrome associated with elevated 
type I interferon expression (table S4) (41). Whilst this STAT2:USP18 interaction has been 
shown to be essential for negative regulation of type I IFN signaling in vitro (40), its significance 
in vivo has not previously been examined. Furthermore, the precise residue(s) of STAT2 that 
bind USP18 were unresolved, although this interaction had been localized to a region including 
the coiled-coil (CCD) and/or DNA-binding domain(s) of STAT2 (40).  
 
STAT2R148W impairs interaction with USP18  
Since USP18 was induced normally in patient cells (Fig. 6A-B) as well as in vivo (Fig. 1B), our 
data implied that STAT2R148W impedes the proper interaction of STAT2 with USP18, 
compromising its regulatory function (Fig. 6C). Indeed, molecular modeling of STAT2R148W 
placed the substituted bulky aromatic tryptophan, and resulting charge change, at an exposed site 
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within the CCD (Fig. 6D). Consistent with our suspicion that this might impair the 
STAT2:USP18 interaction through electrostatic or steric hindrance, co-immunoprecipitation 
experiments in U6A cells stably expressing WT or STAT2R148W demonstrated a significant 
reduction of USP18 pull-down with STAT2R148W compared to WT (Fig. 6E-F), providing a 
molecular mechanism for the USP18 insensitivity of patient cells.  
Whilst disruption to the STAT2R148W:USP18 interaction was the most plausible explanation for 
the clinical and molecular phenotype, we also considered the contribution of alternative 
regulatory functions of STAT2. Beyond the role of tyrosine phosphorylated STAT2 in innate 
IFN signal transduction, the unphosphorylated form of STAT2 (uSTAT2) has additional, 
recently described functions in the regulation of other cytokine signaling pathways. For example, 
uSTAT2 negatively regulates the activity of IFN (and other inflammatory cytokines that signal 
via STAT1 homodimers) by binding to unphosphorylated STAT1 via its CCD (42). This 
interaction appears to limit the pool of STAT1 available for incorporation into transcriptionally 
active (tyrosine phosphorylated) STAT1 homodimers. Conversely, uSTAT2, induced by type I 
IFN signaling, has been reported to promote the transcriptional induction of IL6 through an 
interaction with the NF-B subunit p65 (43). To investigate the potential relevance of these 
regulatory functions of STAT2, we first examined the induction of IL6 by RT-PCR analysis of 
RNA isolated from whole blood of patients, their heterozygous parents and healthy controls. We 
found no evidence of increased expression of IL6, or its target gene SOCS3 (fig. S11A-B), 
consistent with our previous pathway analysis of RNA-seq data (fig. S1) and implying that 
STAT2R148W does not influence IL6 induction. Next, to explore any impact on STAT2’s negative 
regulatory activity towards STAT1, we examined the transcriptional responses to IFN in patient 
fibroblasts and in U6A cells expressing STAT2R148W. Whilst we were able to reproduce the 
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previously reported findings of heightened transcription of the IFN regulated gene CXCL10 in 
U6A cells lacking STAT2, alongside a nonsignificant trend for IRF1 (fig. S12A-B) (42), 
STAT2R148W did not enhance transcript levels of either CXCL10 or IRF1 above WT, in 
agreement with data showing the preserved ability of STAT2R148W to bind STAT1 in a co-
immunoprecipitation assay (fig. S12C-D). Taken together, these studies effectively exclude a 
contribution of the USP18-independent regulatory functions of STAT2 to the disease phenotype. 
 
Insensitivity to USP18 regulation in STAT2R148W patient cells 
To conclusively demonstrate the impairment of STAT2:USP18-mediated negative regulation in 
patient cells, we tested the impact of overexpression or knockdown of USP18. First, we probed 
IFNAR responses in fibroblasts stably expressing USP18. As predicted, USP18 was significantly 
impaired in its ability to suppress IFNα signaling in patient cells, relative to controls, both in 
terms of STAT phosphorylation (Fig. 7A-B) and STAT2 nuclear translocation (Fig. 7C-D), 
recapitulating our prior observations with IFN priming (Fig. 6A). The reciprocal experiment, in 
which USP18 expression was stably knocked down using shRNA, revealed significantly 
prolonged STAT2 phosphorylation in control cells at 24h, recapitulating the phenotype of patient 
cells (Fig. 7E-F). In contrast, there was no effect of USP18 knockdown in patient cells, 
demonstrating that they are USP18-insensitive. Incidentally, we noted that the early peak (1h) of 
STAT2 phosphorylation in USP18-knockdown control fibroblasts was marginally reduced (Fig. 
7E). This subtle reduction was also apparent in STAT2R148W patient fibroblasts (Fig. 4B), 
although not in EBV B cells (Fig. 5). We speculate that the cell-type specific induction of other 
negative regulator(s) of IFNAR signaling at early times post IFN treatment, such as SOCS1, 
might be responsible for this observation. RT-PCR analysis confirmed the increased expression 
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of SOCS1 mRNA in whole blood of patients (fig. S12C), while examination of RNA-seq data 
from IFN-treated fibroblasts revealed an 8-fold enhancement of SOCS1 expression at 6h in 
patient cells as compared to controls (Padj = 0.0001, Fig 4E). Together, these data provide 
preliminary support for the hypothesis that alternative negative regulator(s) of IFNAR signaling 
may be upregulated in patient cells. Nevertheless, such attempts at compensation are clearly 
insufficient to restrain IFNAR responses in the context of STAT2R148W, reflecting the 
nonredundant role of STAT2/USP18 in this process (39).  
Collectively, these data support a model in which the homozygous presence of the Arg148Trp 
STAT2 variant compromises an essential adaptor function of STAT2 towards USP18, rendering 
cells USP18-insensitive and culminating in unrestrained, immunopathogenic IFNAR signaling. 
 
Discussion  
We report a type I interferonopathy, caused by a homozygous missense mutation in STAT2, and 
provide detailed studies to delineate the underlying molecular mechanism. Our data indicate the 
failure of mutant STAT2R148W to support proper negative regulation of IFNAR signaling by 
USP18 - revealing an essential regulatory function of human STAT2. This defect in STAT2 
regulation results in (i) an inability to properly restrain the response to type I IFNs and (ii) the 
genesis of a life-threating early-onset inflammatory disease. This situation presents a marked 
contrast with monogenic STAT2 deficiency, which results in heightened susceptibility to viral 
infection due to the loss of the transcription factor complex ISGF3 (23, 24). Thus, just as allelic 
variants of STAT1 and STAT3 are recognized that either impair or enhance activity of the 
cytokine signaling pathways in which they participate (44), we can now add to this list STAT2. 
Importantly, our findings also highlight an apparently unique property of human STAT2: that it 
 16 
participates directly in both the positive and negative regulation of its own cellular signaling 
pathway. Whether this is true of STAT2 in other species remains to be determined. Our findings 
also localize the interaction with USP18 to the CCD of STAT2, indicating a specific residue 
critical for this interaction. This structural insight may be relevant to efforts to therapeutically 
interfere with the STAT2:USP18 interaction in order to promote the antiviral action of IFNs.   
 
This monogenic disease of STAT2 regulation provides incontrovertible evidence of the 
pathogenic effects of failure to properly restrain IFNAR signaling in humans. The conspicuous 
phenotypic overlap with existing defects of IFNα/β overproduction, particularly with regards to 
the neurological manifestations, provides compelling support for the type I interferonopathy 
hypothesis, strengthening the clinical rationale for therapeutic blockade of IFNAR signaling 
(15). JAK1/2 inhibition with ruxolitinib was highly effective in controlling disease in the 
proband, however the damage already accrued at birth in his younger brother was irreparable, 
emphasizing the importance of timely IFNAR blockade in prevention of neurological sequelae. 
A notable aspect of the clinical phenotype in patient II:3 was the occurrence of severe thrombotic 
microangiopathy (TMA). Our studies did not support a pathogenic contribution of the co-
inherited complement factor H variant in patient II:3. This evidence, together with clinical 
hematological and biochemical results suggestive of incipient vasculopathy in patient II:4 - who 
did not carry the CFH variant - suggests that type I IFN may have directly contributed to the 
development of TMA. Although it is not classically associated with type I interferonopathies, 
TMA is an increasingly recognized complication of both genetic (41, 42) and iatrogenic states of 
IFN excess (43), consistent with the involvement of vasculopathy in the pathomechanism of 
IFN-mediated disease. The fact that STAT2R148W is silent in the heterozygous state at first sight 
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offers a confusing contrast with “gain-of-function” mutations of its sister molecules STAT1 and 
STAT3, both of which produce autosomal dominant disease with high penetrance (26-29). 
However, the net gain of IFNAR signaling activity results from the isolated loss of STAT2’s 
regulatory function, which evidently behaves as a recessive trait. There are other examples of 
autosomal recessive loss-of-function disorders of negative regulators, including USP18 itself (41, 
47); the unique aspect in the case of STAT2R148W is that the affected molecule is itself a key 
positive mediator within the regulated pathway.  
 
In light of the intimate relationship between STAT2 and USP18 revealed by these and other 
recent data (40), it is reasonable to conclude that the clinical manifestations of human USP18 
deficiency are dominated by the loss of its negative feedback towards IFNAR, rather than the 
STAT2-independent functions of USP18 including its enzymatic activity (40, 45, 46). Indeed, 
white matter pathology associated with microglia-specific USP18-deficiency is prevented in the 
absence of IFNAR (21). There are now three human autosomal recessive disorders that directly 
compromise the proper negative regulation of IFNAR signaling and thus produce a net gain of 
signaling function: USP18 deficiency, which leads to embryonic or neonatal lethality with severe 
multisystem inflammation (41); STAT2R148W, which largely phenocopies USP18 deficiency; and 
ISG15 deficiency, in which there is a much milder phenotype of neurological disease without 
systemic inflammation (47). ISG15 stabilizes USP18, and human ISG15 deficiency leads to a 
partial loss of USP18 protein (41). Thus, a correlation is clearly evident between the extent of 
USP18 dysfunction and the clinical severity of these disorders, with STAT2R148W closer to 
USP18 deficiency and ISG15 on the milder end of the spectrum (table S4). It is also notable that 
those molecular defects that result in a failure of negative regulation of IFNAR signaling (i.e. 
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STAT2R148W and USP18-/-) lead to more serious and extensive systemic inflammatory disease 
than do defects of excessive IFNα/β production (41), suggesting that the STAT2:USP18 axis acts 
to limit an immunopathogenic response towards both physiological (48) and pathological (41) 
levels of IFNα/β. Thus, variability in the efficiency of this process of negative regulation might 
be predicted to influence the clinical expressivity of interferonopathies. Determining the cellular 
source(s) of ‘physiological’ type I IFNs and the molecular pathways that regulate their 
production are important areas for future investigation. 
 
Some limitations of our results should be acknowledged. Although strenuous efforts were made, 
we were only able to identify a single kindred, which probably reflects the rarity of this variant. 
As more cases are identified our understanding of the clinical phenotypic spectrum will 
inevitably expand. Furthermore, for practical and cultural/ethical reasons, limited amounts of 
cellular material and tissues were available for analysis. As a result, we were unable to formally 
evaluate the relevance of STAT2 regulation towards type III IFN signaling; however, existing 
data suggest that USP18 plays a negligible role in this context (38). Taken together, our findings 
confirm an essential regulatory role of STAT2, supporting the hypothesis that type I IFNs play a 
causal role in a diverse spectrum of human disease, with immediate therapeutic implications. 
 
Study design 
We investigated a kindred with a severe, early-onset, presumed genetic disease, seeking to 
determine the underlying pathomechanism by ex vivo and in vitro studies. Written informed 
consent for these studies was provided, and ethical/instiutional approval was granted by the 
NRES Committee North East - Newcastle & North Tyneside 1 (Ref: 16/NE/0002), South Central 
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- Hampshire A (Ref: 17/SC/0026) and Leeds (East) (Ref: 07/Q1206/7). 
 
Materials and Methods 
 
Cells, cytokines and inhibitors: Dermal fibroblasts from patient II:3 and healthy controls were 
obtained by standard methods and cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented by 10% fetal calf serum and 1% penicillin/streptomycin (DMEM-10), as were 
HEK 293T cells and the STAT2-deficient human sarcoma cell line U6A (31). Peripheral blood 
mononuclear cells (PBMCs) and Epstein Barr virus (EBV)-transformed B cells were cultured in 
RPMI medium supplemented by 10% fetal calf serum and 1% penicillin/streptomycin (RPMI-
10). Unless otherwise stated, cytokines/inhibitors were used at the following concentrations: 
Human recombinant interferon-2b (Intron-A, Schering-Plough, USA) 1000 IU/mL; interferon- 
(Immunikin, Boehringer Ingelheim, Germany), 1000 IU/mL; IL6 (Peprotech, USA), 25 ng/mL; 
staurosporine (ALX-380-014-C250, Enzo Life Sciences, N.Y., USA), 500 nM. Diagnostic 
histopathology, immunology and virology studies were conducted in accredited regional 
diagnostic laboratories to standard protocols. 
 
Whole exome sequencing: Whole exome sequencing (WES) analysis was performed on DNA 
isolated from whole blood from patients I:1, I:2, II:3 and II:4. Capture and library preparation 
was undertaken using the BGI V4 exome kit (BGI, Beijing, China) according to manufacturer’s 
instructions, and sequencing was performed on a BGISEQ (BGI). Bioinformatics analysis and 
variant confirmation by Sanger sequencing are described in supplemental materials (SM). 
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qRT-PCR: RNA was extracted by lysing fibroblasts in TRIzol® reagent (ThermoFisher 
Scientific) or from whole blood samples collected in PAXgene® tubes (PreAnalytix), as 
described previously (49). Further details, including primer/probe information, are summarized 
in SM and table S5.  
 
RNA sequencing: Whole blood transcriptome expression analysis was performed using 9 whole 
blood samples from the proband taken before and during treatment, and 5 controls. Additionally 
the 4 patient II:3 samples taken before treatment, as well as samples from 6 patients with 
mutations in TREX1, 3 with mutations in RNASEH2A, 7 with mutations in RNASEH2B, 5 with 
mutations in RNASEH2C, 5 with mutations in SAMHD1, 4 with mutations in ADAR1, 2 with 
mutations in IFIH1, 3 with mutations in ACP5, 3 with mutations in TMEM173 and 3 with 
mutations in DNASE2 were analyzed, as described in SM. RNA integrity was analyzed with 
Agilent 2100 Bioanalyzer (Agilent Technologies). mRNA purification and fragmentation, 
complementary DNA synthesis and target amplification were performed using the Illumina® 
TruSeq RNA Sample Preparation Kit (Illumina). Pooled cDNA libraries were sequenced using 
the HiSeq 4000 Illumina® platform (Illumina). Fibroblasts grown in 6-well plates were mock 
treated or treated with IFN for 6h, or for 12h followed by extensive washing and 36h rest, prior 
to RNA extraction. The experiment was performed with patient II:3 and control cells (n=3) in 
triplicate per timepoint. RNA was extracted using the ReliaPrep™ RNA Miniprep kit (Promega) 
according to manufacturer’s instructions and processed as described above, before sequencing on 
an Illumina® NextSeq500 platform. Bioinformatic analysis is described in SM. PMBC and 
fibroblast STAT2 patient and control data have been deposited in Array Express (E-MTAB-
7275) and Gene Expression Omnibus respectively (GSE119709).  
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Lentiviral transduction: Details of lentiviral constructs, mutagenesis and preparation are 
included in SM. Cells were spinoculated in 6-well plates for 1.5 h at 2000 rpm, with target or 
null control viral particles, at various dilutions in a total volume of 0.5mL DMEM-10 containing 
hexadimethrine bromide (Polybrene, 8 g/mL, Sigma-Aldrich). Cells were rested in virus-
containing medium for 8 h then incubated in fresh DMEM-10 until 48 h, when they were 
subjected to selection with 2.0 g/mL puromycin or 2.5 g/mL blastocidin (Sigma-Aldrich). 
Antibiotic-containing medium was refreshed every 72 h.  
 
Flow cytometry: EBV B cells were seeded at a density of 8x105 cells/mL in serum-free 
XVIVO-15 medium (Lonza, Basel, Switzerland) and stimulated with IFNα (1000 IU/mL) for the 
indicated times. After staining with Zombie UV (BioLegend, San Diego, California, USA), cells 
were fixed using Cytofix buffer (BD Biosciences, Franklin Lakes, NJ, USA). Permeabilization 
was achieved by adding ice-cold PermIII buffer (BD Biosciences, Franklin Lakes, NJ, USA) and 
incubating the cells for 20 minutes on ice. After repeated washing steps with PBS/2% FBS, cells 
were stained for 60 minutes at room temperature with directly-conjugated antibodies (table S6). 
Samples were acquired on a Symphony A5 flow cytometer (BD) and analyzed using FlowJo 
(Flowjo LLC, Ashland, OR, USA). The gating strategy is shown in fig. S13. 
 
Immunoblotting: Immunoblotting was carried out as previously described (1) and analyzed 
using either a G:BOX Chemi (Syngene, Hyarana, India) CCD camera with Genesnap software 
(Syngene) or a LI-COR Odyssey Fc (LI-COR, Nebraska, USA). Densitometry analysis was 
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undertaken using ImageStudio software (Version 5.2.5, Li-COR). For complement studies, SDS-
PAGE under non-reducing conditions was performed on patient/parental serum (diluted 1:125 in 
non-reducing buffer [PBS]) or affinity-purified factor H (diluted to 200 ng in non-reducing 
buffer), separated by electrophoresis on a 6% SDS-PAGE gel and transferred to nitrocellulose 
membranes for immunoblotting (antibodies in table S6). Blots were developed with Pierce ECL 
Western blotting substrate (ThermoFisher Scientific) and imaged on a LI-COR Odyssey Fc (LI-
COR).  
 
Immunoprecipitation: U6A cells were lysed in IP buffer (25 mM Tris pH 7.4, 1 mM EDTA, 
150 mM NaCl, 1% Nonidet P-40, 1 mM sodium orthovanadate, 10 mM sodium fluoride, with 
complete protease inhibitor [Roche, Basel, Switzerland]). Lysates were centrifuged at 13,000 
rpm at 4°C for 10 min. Soluble fractions were precleared for 1 hour at 4°C with Protein G 
Sepharose 4 (Fast Flow, GE Healthcare, Chicago, USA) that had been previously blocked with 
1% BSA IP buffer for 1 hour. Precleared cell lysates were immunoprecipitated overnight with 
blocked beads that were incubated with anti-STAT2 antibody (A-7) for 1 hour and then washed 
three times in IP buffer before boiling with 4 × LDS buffer at 95°C for 10 min to elute the 
absorbed immunocomplexes. Immunoblot was carried out as described above.  
 
Immunofluorescence: Fibroblasts grown on 8-well chamber slides (Ibidi, Martinsried, 
Germany) were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) for 15 min 
at RT prior to blocking/permeabilization with 3% BSA/0.1% Triton™ X-100 (Sigma-Aldrich) in 
PBS. Cells were incubated with anti-STAT2 primary antibody (C20, Santa-Cruz Biotechnology, 
Dallas, USA) overnight at 4˚C (10 μg/mL) and cells were washed three times with PBS. 
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Secondary antibody (goat anti-rabbit Alexa Fluor 488, 1 μg/mL, ThermoFisher Scientific) 
incubation was performed for 1h at RT, followed by nuclear staining with 0.2 μg/mL 4',6-
diamidino-2-phenylindole (DAPI, ThermoFisher Scientific). Cells were imaged with an EVOS 
FL fluorescence microscope with a 10x objective (ThermoFisher Scientific). The use of STAT2-
deficient cells (23) demonstrated the specificity and lack of non-specific background of the 
staining approach (not shown). Image analysis was performed in ImageJ. The DAPI (nuclear) 
image was converted to binary and each nucleus (object) counted. This mask was overlaid onto 
the STAT2 image and the mean fluorescence intensity of STAT2 within each nucleus calculated 
(see also Fig. S9). Approximately n=100 cells were analyzed per image.     
 
Structural Analysis: The structure of human STAT2 has not been experimentally determined.  
We therefore used comparative modelling to predict the structure.  The sequences of both the 
wild type and mutant were aligned to mouse STAT2 (pdb code 5OEN, chain B).  For each 
sequence twenty models were built using MODELLER (50) and the one with the lowest discrete 
optimized protein energy score was chosen.  Protein structures and electrostatic surfaces were 
visualized with PyMOL (Schrodinger, USA). 
 
Cytotoxicity assay: Fibroblasts grown on 96-well plates were treated with IFN (1000 or 
10,000 IU/mL) or DMEM-10 alone for 72 hours. Cells were fixed in PBS containing 5% 
formaldehyde for 15 min at RT and then incubated with crystal violet stain. Plates were washed 
extensively then allowed to air dry. The remaining cell membrane-bound stain was solubilized 
with methanol and absorbance at 595 nm measured on a TECAN SunriseTM plate reader (Tecan, 
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Switzerland). Background absorbance was subtracted from all samples and the results expressed 
as a percentage of the absorbance values of untreated cells. 
 
Antiviral protection assay: Fibroblasts grown on 96-well plates were pre-treated in septuplicate 
for 18 hours with two-fold serial dilutions of IFN and IFN followed by infection with 
mCherry-expressing parainfluenza virus 5 (PIV5) in DMEM/2% FBS for 24 hours. Monolayers 
were fixed with PBS containing 5% formaldehyde and infection was quantified by measuring 
mean fluorescence intensity of mCherry (Ex 580/9, Em 610/20) using a TECAN Infinite M200 
Pro plate reader (Tecan, Switzerland). Background fluorescence was subtracted from all samples 
and the results expressed as a percentage of the fluorescence values of untreated, virus-infected 
cells. 
 
Statistical analysis: Unless otherwise stated all experiments were repeated a minimum of three 
times. Data were normalized/log10-transformed prior to parametric tests of significance in view 
of the limitations of ascertaining distribution in small sample sizes and the high type II error rates 
of nonparametric tests in this context. Comparison of two groups used t test, or one-sample t test 
if data were normalized to control values. Comparisons of more than one group used one-way 
ANOVA or two-way ANOVA as appropriate, with post-test correction for multiple comparisons. 
Statistical testing was undertaken in GraphPad Prism (v7.0). All tests were two-tailed with alpha 
 0.05.  
 
Supplementary Materials: 
 25 
Materials and methods 
Case summary 
Fig. S1. Ingenuity pathway analysis of whole blood RNA-seq data.  
Fig. S2. Longitudinal series of laboratory parameters. 
Fig. S3. Multiple sequence alignment of STAT2. 
Fig. S4. Factor H genotyping and mutant factor H purification strategy. 
Fig. S5. Functional analysis of factor H (FH) Tyr779Cys variant.  
Fig. S6. Immunoblot analysis of MX1 expression in PBMCs. 
Fig. S7. Transduction of STAT2-deficient primary fibroblasts. 
Fig. S8. Prolonged STAT2 phosphorylation in PBMCs. 
Fig. S9. STAT2 immunofluorescence image analysis. 
Fig. S10. STAT phosphorylation is not prolonged in patient cells by IFN or IL6. 
Fig. S11. RT-PCR analysis of gene expression in whole blood.  
Fig. S12. STAT2R148W does not impair regulation of STAT1 signaling.  
Fig. S13. Phosflow gating strategy. 
Table S1. Laboratory parameters, patients II:3 and II:4. 
Table S2. Rare variants segregating with disease. 
Table S3. Digital ELISA detection of IFN protein concentration.  
Table S4. Phenotypes of monogenic defects of USP18 expression and/or function. 
 26 
Table S5. RT-PCR primers and probes.  
Table S6. Antibodies. 
Data file S1. Raw data (Excel). 
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Figure captions 
Fig. 1. Neurological and systemic disease associated with excessive IFN activity.  
(A) Neuroimaging demonstrating calcifications (brainstem/hypothalamus [proband II:3, top 
panel]; cerebral white matter/basal ganglia/midbrain/optic tract [sibling II:4, top and middle]); 
hemorrhages (occipital/subdural/subarachnoid [proband II:3, middle]); cerebral white matter and 
cerebellar signal abnormality with parenchymal volume loss (both, bottom), accompanied by 
focal cystic change and cerebellar atrophy (sibling II:4).  (B) Whole blood RNA-seq interferon 
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stimulated gene profiles: controls (n=5); proband II:3 (n=4); patients with mutations in: TREX1 
(n=6); RNASEH2A (n=3); RNASEH2B (n=7); RNASEH2C (n=5); SAMHD1 (n=5); ADAR1 
(n=4); IFIH1 (n=2); ACP5 (n=3); TMEM173 (n=3); DNASE2 (n=3). (C) Interferon scores (RT-
PCR) of patients, parents and n=29 healthy controls. **** P<0.001, ANOVA with Dunnett’s 
post-test. (D) Renal histopathology in proband (x 400 magnification) showing thrombotic 
microangiopathy with extensive double contouring of capillary walls (silver stain, upper left 
panel), endothelial swelling, mesangiolysis and red cell fragmentation (upper right), arteriolar 
fibrinoid necrosis (lower left) and myxoid intimal thickening of an interlobular artery (lower 
right, all H&E). (E) Transcriptional response to JAK inhibitor (JAKi) ruxolitinib in both patients 
(RT-PCR). 
 
Fig. 2. A homozygous missense variant in STAT2 consistent with autosomal recessive 
inheritance. (A) pedigree (B) capillary sequencing verification (C) protein map and (D) 
immunoblot (fibroblasts) showing normal expression of STAT2 protein.  
 
Fig. 3. Heightened sensitivity to IFNα in cells bearing STAT2R148W. Unless stated all data are 
from patient II:3 and control fibroblasts. (A) ISG expression (immunoblot, 24h IFNα) and (B) 
densitometry analysis (n=3, t test). (C) IFNB mRNA (RT-PCR) ± external poly I:C treatment 
(25µg/mL 4h, n=3, t test). (D) Antiviral protection assay (mCherry-PIV5). 2-fold dilutions from 
16 IU/mL IFNα, 160 IU/mL IFN n=7 replicates, representative of n=2 experiments (two-way 
ANOVA with Sidak’s post-test). (E) Cytopathicity assay (72h IFNα, n=3, t test). (F) As in (A) 
ISG expression in STAT2-/- U6A cells reconstituted with STAT2WT or STAT2R148W 
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(immunoblot, 24h IFNα). (G) as in (B) n=3-4, t test. Data are presented as mean ± SEM of repeat 
experiments. *P<0.05, ** <0.01 *** <0.001, **** <0.0001, n.s.= nonsignificant. 
 
Fig. 4. Prolonged STAT2 activation but no change to dephosphorylation rate. All data are from 
patient II:3 and control fibroblasts. (A) pSTAT2 timecourse (immunoblot, 1000 IU/mL IFNα) 
and (B) densitometry analysis (n=5 experiments, two-way ANOVA with Sidak’s post-test). (C) 
Immunofluorescence analysis (1000 IU/mL IFNα, scale bar = 100µm, representative of n=3 
experiments) with (D) image analysis of STAT2 nuclear translocation (n=100 cells/condition, 
ANOVA with Sidak’s post-test). (E) RNA-seq analysis of interferon-regulated genes (n=3 
controls) with (F) validation by RT-PCR (n=3, two-way ANOVA with Sidak’s post-test). (G) 
pSTAT2 decay (immunoblot). 1000 IU/mL IFNα (30 min) followed by extensive washing and 
treatment with 500nM staurosporine (STAU). Times relative to STAU treatment. (H) No 
significant differences by densitometry analysis (n=3, t test). Data are presented as mean ± SEM 
of repeat experiments. *P<0.05, ** <0.01 *** <0.001, **** <0.0001, n.s.= nonsignificant. 
 
Fig. 5. Prolonged proximal IFNAR signaling in STAT2R148W homozygosity, but not 
heterozygosity. Timecourse of IFNα stimulation (1000 IU/mL) in EBV-B cells from patient II:3 
(hom), parent I:2 (het) and n=3 controls. (A) immunoblot and (B) densitometry analysis. (C) 
Representative histograms (flow cytometry) and (D) mean fluorescence intensity. Data are mean 
± SEM of three repeat experiments (*P<0.05, ** <0.01, n.s.= nonsignificant, t test). 
 
Fig. 6. STAT2R148W fails to support desensitization through its impaired interaction with USP18. 
(A) Desensitization assay (immunoblot, fibroblasts) with (B) pSTAT densitometry analysis 
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(pSTAT/tubulin, ratio to unprimed, n=4, ANOVA with Sidak’s post-test). (C) Schematic of 
USP18 mechanism of action and proposed model of STAT2R148W pathomechanism. (D) 
Modelling of exposed WT (R148)/mutant (W148) residue, demonstrating charge-change (blue = 
positive, red = negative) and possible steric restriction. (E) Co-immunoprecipitation of USP18 
by STAT2 in U6A cells expressing STAT2WT or STAT2R148W with (F) densitometry analysis 
(USP18/STAT2, ratio to WT, one-sample t test). Data are mean ± SEM (** P<0.01, **** 
<0.0001).  
 
Fig. 7. USP18 insensitivity in cells bearing STAT2R148W. All data are from patient II:3 and 
control fibroblasts. (A) STAT phosphorylation in USP18 and vector expressing fibroblasts 
(immunoblot) with (B) pSTAT densitometry analysis (pSTAT/tubulin, ratio to unprimed, n=3, 
ANOVA with Sidak’s post-test). (C) Immunofluorescence analysis of STAT2 nuclear 
translocation (1000 IU/ml IFNα, scale bar = 100µm, representative of n=3 experiments ) with 
(D) image analysis (n=100 cells/condition, ANOVA with Sidak’s post-test). (E) Timecourse of 
STAT phosphorylation upon IFNα stimulation (1000 IU/mL for 0, 1, 6 and 24 h) of cells 
transduced with USP18 shRNA or non-targeting (NT) shRNA with (F) densitometry analysis of 
pSTAT2 (n=3, t test). Data are mean ± SEM (** P<0.01, *** <0.001, **** <0.0001, ns = 
nonsignificant).  
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Clinical Feature Proband (II:3)  Sibling (II:4) 
Premature birth Yes Yes 
Neonatal thrombocytopenia Yes No 
Apnea requiring respiratory support Yes Yes 
Seizures Yes Abnormal EEG 
Developmental delay Yes Yes 
White matter changes Yes Yes 
Intracranial calcification Yes Yes 
Intracerebral hemorrhage Yes Yes 
Cerebellar hypoplasia No Yes 
Sterile fevers Yes No 
HLH-like inflammation  Yes No 
Hyperferritinemia Yes Borderline 
Hypertension Yes Borderline 
Acute kidney injury Yes No 
Proteinuria Yes Yes 
Thrombotic microangiopathy Yes Possible 
Elevated D-dimers Yes Yes 
High ISG score Yes Yes 
Age at death 20 months 3 months 
Table 1. Clinical phenotype of affected individuals. HLH = hemophagocytic 
lymphohistiocytosis; ISG = interferon-stimulated gene.  
 
